Quanterix Corporation · NASDAQ:QTRX
Quanterix — Q2 2022 Earnings Presentation
13 slides from Quanterix's earnings presentation, Aug 8, 2022
Slide 1: Q2 2022 Earnings Call
Quanterix’ Q2 2022 Earnings Call August 8, 2022
Slide 2: Forward-Looking Statements & Pro-Forma Financial Measures
Forward-Looking Statements & Pro-Forma Financial Measures This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as we
Slide 3: Q2 2022 Pro-Forma Results
Q2 2022 Pro-Forma Results Q2 2021 a2 2022 Revenue $ 25.4 23:5 GM$ * 12.0 6.6 GM% * 47.5% 28.3% Operating Loss -13.7 -25.0 Operating Loss -53.9% 106.2% as % of Revenue *Reconciliation of Pro-Forma Gross Margin included on slide 7 Quanterix INSTRUMENTS CONSUMABLES LERATOR | OTHER SERVICES 24% Wi Q2 20
Slide 4: 1H 2022 Pro-Forma Results
1H 2022 Pro-Forma Results 1H 2021 41H 2022 Revenue $ 52.6 53.4 Mix 22% 45% 23% 10% GM$ * 26.7 19.3 1H 2021 MM Q2 2022 GM% * 50.7% 36.5% | a 24.1 23.6 Operating Loss -23.5 -43.1 & = +55% m ial a 8 ‘| 8 12.1 +20% jperating Loss . " e a -100% as % of Revenue 44.6% ae ian ao | 4.6 5.5 *Reconciliation of
Slide 5: Q1'22 to Q2'22 Pro-Forma Gross Margin Contribution
Q1’22 to Q2 ‘22 Pro-Forma Gross Margin Contribution 49.3% T7A% 8.1% 43.4% 371% 8.8% 28.3% 11.6 Q1 2022 COGS Mix/Volume E&O Q2 2022 Freightcost Q2 2022 GAAP Allocation Reserves GAAP Pro-Forma * *Reconciliation of Pro-Forma Gross Margin included on slide 7 Quanterix
Slide 6: Q1'22 to Q2'22 Pro-Forma Operating Expense
Q1’22 to Q2 ‘22 Pro-Forma Operating Expense —=| ZZ! 31.6 -2.1 Q1 2022 GAAP Stock Comp Merit Facility COGS Allocation Q2 2022 GAAP Freight cost Q1 2022 Expansion Pro-Forma * & Other *Reconciliation of Pro-Forma Operating Expense included on slide 7 Quanterix
Slide 7: Reconciliation of GAAP to Pro Forma
Reconciliation of GAAP to Pro Forma Reconciliation of GAAP to Pro Forma (In thousands) 0 0 0 0 Gross profit 8,711 13,874 23,270 30,223 Distribution Costs (Note 1) (2,065) (1,827) (3,929) (3,562) Pro forma gross profit 6,646 12,047 19,341 26,661 GAAP gross margin % 37.1% 54.7% 43.9% 57.5% Pro forma g
Slide 8: Scientific Validation Driving Adoption
Scientific Validation Driving Adoption IH Neurology Immunology & Oncology Il Infectious Diseases J Others 2022 Advances Cumulative Cumulative Placements 518 " # of units placed 1.845 480 Cumulative 798 708 403 322 535 259 400 278 bs 18 19 20 a YTD 22 18 19 20 2 YTD 22 18 19 20 2 YTD 22 va ) e | « .
Slide 9: Q2 2022 Revenue Stratification
Q2 2022 Revenue Stratification GEOGRAPHY 62% YoY GROWTH m NA @ Europe Quanterix 5% 10% 43% @ Pharma/CROs -6.2% i Academia 8.3% @ Neurology “14% @ Oncology* 96% @ Others -34% * Incl. immunology & Inflammation PRODUCTS | & SERVICES . 39% YoY GROWTH @ Consumables @ Accelerator -29% 66%
Slide 10: The first pTau-181 plasma test released for clinical use in the U.S
The first pTau-181 plasma test released for clinical use in the U.S Results of the validation study presented at 2022 Alzheimer’s Association International Conference Background Detection Quanterix announced . Ellen omunnassay annenod - phaspbotas esr TOS ae) pnlquely ; ‘dati or the measurement of p
Slide 11: Increasing Investment in Neurodegenerative Disease
Increasing Investment in Neurodegenerative Disease Growth in neurodegenerative disease research and drug development investments Trends in NIH Funding: 2017 - 2022 Trends in Active Clinical Trials =Phase 1 =Phase2 =Phase3 =Phase 4 Alzheimer's Disease Non-AD Neurological Disease $9,000 $8,000 | $600
Slide 12: Quanterix Enabling the Full Drug Development Continuum
Quanterix Enabling the Full Drug Development Continuum Simoa technology accelerating drug approval from basic research to post-market clinical studies safety & effectiveness & safety & safety effectiveness side effects optimal use Volunteers Needed 10s 100s 1000s Early Phase Biomarker Research ks Tr
Slide 13: Patient Selection Strategy Can Accelerate Drug Approval
Patient Selection Strategy Can Accelerate Drug Approval Simoa Blood-Based Patient Screening Can Reduce Trial Costs & Accelerate Enrollment Representative Clinical Trial Design Late-Stage Clinical Trial Disease modifying therapy for Alzheimer's Inclusion Criteria Cognitively unimpaired PET+ (various